Keywords: Cancer Research UK, Aura Biosciences, USA, KLicensing, Cancer-targeting peptides
CRT grants rights for targeting technology to Aura
Article | 24 December 2009
Cancer Research Technology (CRT), Cancer Research UK’s commercialization and development arm, has granted Cambridge, Massachusetts, USA-based Aura Biosciences a worldwide licence to use its cancer-targeting peptides in delivering cancer treatments directly to the tumour.
These peptides bind to a protein on the surface of the cell called integrin alpha v beta 6, a protein complex that is found at high levels on many tumor cells but is absent in most normal tissues. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Want to read the full article?
Take a 30 day FREE Trial worth £60
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Pfizer acts to stop Mylan marketing generic Chantix; Allergan in $600 million settlement over Botox marketing practices
- PDL BioPharma sues Roche’s Genentech over royalties
- Novartis/NIH-sponsored research yields promising malaria drug candidate
- Indian’s Ranbaxy inaugurates new $30 million drug manufacturing facility in South Africa
- Seattle Genetics gets milestone as Astellas unit moves cancer drug into Ph I
